BioMarin Pharmaceutical’s VP and Chief Accounting Officer, Rashmi Virendra Ramchandani, reported new equity awards. On January 20, 2026, she received 18,540 shares of common stock and a separate grant of 7,070 shares, both at a stated price of $0, which the footnotes describe as restricted stock units granted on that date. After these awards, she directly beneficially owned 25,610 common shares.
She was also granted a stock option covering 18,220 shares of common stock at an exercise price of $56.31 per share. The option becomes exercisable as to 12/48 of the grant on January 20, 2027, with the remaining 1/48 vesting on the 20th day of each month thereafter, and it expires on January 19, 2036. These transactions reflect equity compensation rather than open‑market buying or selling.
BioMarin Pharmaceutical Inc. insider filing shows no holdings for a new officer. VP and Chief Accounting Officer Rashmi Virendra Ramchandani filed an initial ownership report on Form 3 for BioMarin Pharmaceutical Inc. The filing states that no securities of BioMarin are beneficially owned. This means that, as of the event date shown in the filing, the reporting officer does not report owning any shares or derivative securities of the company.
BioMarin Pharmaceutical Inc. reports that BlackRock, Inc. beneficially owns 17,560,751 shares of its common stock, representing 9.1% of the class as of December 31, 2025. BlackRock has sole voting power over 16,727,815 shares and sole dispositive power over 17,560,751 shares, with no shared voting or dispositive authority.
The shares are held across various clients and funds, and no single underlying person has more than five percent of BioMarin’s outstanding common stock. BlackRock states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of BioMarin.
BioMarin Pharmaceutical Inc. provided a preliminary financial update alongside its presentation at the J.P. Morgan Healthcare Conference. Based on unaudited results, the company estimates it generated approximately $3.2 billion in total revenues for the year ended December 31, 2025, including about $920 million from VOXZOGO® sales for the same period. BioMarin also expects an asset write-down related to ROCTAVIAN in the fourth quarter of 2025 of approximately $230 million to $260 million.
Of this write-down, around $120 million to $125 million, or roughly $(0.60) to $(0.64) per diluted share assuming about 200 million weighted-average diluted shares outstanding, is expected to reduce the company’s Non-GAAP Income and Non-GAAP Diluted EPS for 2025. Excluding the impact of this asset write-down, BioMarin states that its previously issued full-year 2025 Non-GAAP Diluted EPS guidance remains unchanged. All figures are preliminary, unaudited, and subject to normal year-end closing procedures.
BioMarin Pharmaceutical Inc. reported that it has appointed Rashmi Ramchandani as Vice President, Chief Accounting Officer, effective January 19, 2026. In this role she will also become the company’s principal accounting officer, while Brian Mueller will remain Executive Vice President, Chief Financial Officer and principal financial officer.
Ramchandani brings more than two decades of accounting and finance experience, including senior roles at Gilead Sciences and Strava, and is a CPA with a BA in Accounting and Psychology. Her compensation package includes a $460,000 annual base salary, a $400,000 sign-on bonus, eligibility for an annual bonus targeted at 45% of base salary starting in 2026, and equity awards of restricted stock units valued at $1,050,000 and $400,000 plus stock options valued at $450,000, all subject to time-based vesting and continued service.
The sign-on bonus must be repaid if her employment ends within two years under most circumstances, and the company states she has no related party transactions requiring disclosure.
BioMarin Pharmaceutical Inc. reported Q3 2025 results showing steady sales but a GAAP loss driven by R&D charges. Total revenue was $776.1 million, up from $745.7 million a year ago. Product leaders were VOXZOGO $218.4M, VIMIZIM $182.8M, and PALYNZIQ $108.8M; ALDURAZYME delivered $53.7M and ROCTAVIAN $3.2M.
Operating expenses rose to $822.8 million as R&D reached $409.5M, reflecting a $221.0M acquired in-process R&D charge tied to the Inozyme transaction. The quarter posted a net loss of $30.7M (diluted EPS $(0.16)) versus net income of $106.1M (EPS $0.55) last year. Year‑to‑date, revenue was $2,346.7M with net income $395.5M (diluted EPS $2.04), supported by operating cash flow of $728.4M.
Liquidity remained strong with cash and cash equivalents $1,250.1M, short‑term investments $227.7M, and long‑term investments $512.9M. Total assets were $7.61B. The company has $600.0M of 1.25% convertible notes due 2027. BioMarin completed the Inozyme acquisition (total consideration $329.1M), adding late‑stage enzyme therapy BMN 401; management also plans to pursue options to divest ROCTAVIAN.
BioMarin Pharmaceutical Inc. announced financial results for the third quarter ended September 30, 2025. The company furnished a press release dated October 27, 2025 as Exhibit 99.1.
The press release is furnished and not deemed filed, and the company also included the cover page Inline XBRL data as Exhibit 104.
BioMarin Pharmaceuticals filed an 8-K disclosing its use and definition of Non-GAAP Diluted EPS and related Non-GAAP measures. The filing explains Non-GAAP Diluted EPS as Non-GAAP Income divided by Non-GAAP weighted-average diluted shares outstanding, and defines reconciling adjustments that may exclude amortization of intangible assets, stock-based compensation expense and certain other specified items, plus an estimated tax impact for those adjustments. The company says it uses both GAAP and Non-GAAP results internally to assess operating performance and guide business decisions in its core activities: discovery, development, manufacture, marketing and sale of biologic therapies. The filing cautions that these measures are not prepared under GAAP, have no standardized meaning, and may be calculated differently than similarly named metrics at other companies.
BioMarin Pharmaceutical insider Gregory R. Friberg, listed as Executive Vice President and Chief R&D Officer, reported a sale of 3,304 shares of BioMarin common stock on 09/30/2025 at a price of $54.16 per share. After the transaction, the reporting person beneficially owned 43,506 shares. The Form 4 was signed on 10/02/2025 by an attorney-in-fact.
Viking Global and affiliated funds report a 6.4% common-stock stake in BioMarin Pharmaceuticals (BMRN). Collectively the Reporting Persons beneficially own 12,288,611 shares out of 192,001,650 shares outstanding as of June 30, 2025. Ownership is shared (no reported sole voting or dispositive power); the holdings are held across several Viking entities and funds (largest positions reported: Viking Global Investors LP 12,288,611; Viking Global Performance LLC 8,208,825; Viking Global Equities Master Ltd. 8,044,650; Viking Long Fund Master Ltd. 2,856,671; Viking Global Opportunities Liquid Portfolio Sub-Master LP 1,223,115). The filing states the securities were not acquired to change or influence control of the issuer. Signatures on the amendment are dated August 14, 2025.